ProMIS Neurosciences Announces First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 12, 2025
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease
Six Month Interim Results Expected in 1H 2026
Read more at globenewswire.com
